immatics receives €22 million final tranche of Series D fundraising

Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics’ Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies July 16, 2014 immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has received €22m to complete a Series …